Browsing tag:

anemia


At the end of January 2014 the powerful drug Eculizumab received orphan drug status from the FDA as a preventative treatment of delayed graft function (DGF) for renal transplant patients. Eculizumab is already approved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Paroxysmal nocturnal hemoglobinuria or PNH is a rare form of anemia[…]

Read More

On February 3, 2014 the FDA announced their decision to grant breakthrough therapy status to the formidable anemia medication Eltrombopag. The Eltrombopag breakthrough therapy status is based on successful data from a Phase 2 study of Eltrombopag in patients with severe aplastic anemia. The aforementioned study participants were ideal for treatment with Eltrombopag as they[…]

Read More

Lenalidomide created quite a stir on Wall Street on July 11, 2013 when shares of Celgene’s Revlimid, the brand name of Lenalidomide, soared. The frenzy occurred after Celgene released data from the Phase 3 study of Lenalidomide, revealing  the great success of this blood cancer drug. Lenalidomide proved in Phase 3 studies to effectively halt[…]

Read More

Ruxolitinib, CAS number 941678-49-5, is a kinase inhibitor and used to treat myelofibrosis. The condition of myelofibrosis is one that involves the bone marrow being replaced by scar tissue, therefore causing a decreased blood cell production in patients. Ruxolitinib is effective at blocking the enzymes, janus-associated kinase, or JAK 1 and 2, which causes scar[…]

Read More

Anti-diabetic drugs treat diabetes by lowering glucose levels in the blood. One class of anti-diabetic drugs that are used in the management of diabetes is Sulfonylurea. Sulfonylurea derivatives are used in the management of diabetes mellitus type 2.  They act by increasing insulin release from the beta cells in the pancreas.  Diabetes mellitus type 2[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service